As cancer care becomes increasingly personalized and complex, scientific progress matters most when it reaches the patients who need it, and patients, caregivers, and healthcare professionals need clear information to act on it. From education on the importance of biomarker testing in gastric cancer to tailored resources for small cell lung cancer, accessible resources help turn complex clinical information into meaningful, actionable conversations about care.

Progress in rare cancer research is often measured in scientific milestones, but its true foundation lies in the people who make those milestones possible. Patients, families, clinicians and advocates each play a vital role in advancing research, and why meaningful breakthroughs in rare cancers are never achieved alone.

We’ve placed a strategic focus on HER2 development to help address the ongoing unmet needs faced by patients and their families. Learn how the landscape of HER2-targeted agents in cancer care is evolving and how we’re continuing to build our HER2 platform to drive long-term impact for patients and their families

The pace of progress in oncology continues to accelerate, driven by a deeper understanding of tumor biology and increasingly precise therapeutic approaches. That momentum is particularly meaningful in rare cancers, where unmet need remains high and rigorous science has the potential to make a real difference for patients.

Corporate Sustainability and Social Impact, or CSSI, helps us embed the needs of patients, our people, communities, and the planet into how we operate and make decisions. It is a business discipline that supports trust, resilience, and long-term value.

We recognize that living with a complex sleep disorder extends far beyond the core symptoms and profoundly impacts every facet of a person’s life. For years, we have worked to better understand the complex, multifaceted realities faced by individuals living with these often-misunderstood conditions.